Patterns of corticosteroid use among remdesivir and matched patients and associated clinical outcomes in hospitalized COVID-19 patients

被引:0
|
作者
Papic, Ivan [1 ]
Bistrovic, Petra [2 ]
Keres, Tatjana [3 ]
Hadziabdic, Maja Ortner [4 ]
Lucijanic, Marko [5 ,6 ,7 ]
机构
[1] Univ Hosp Dubrava, Pharm Dept, Zagreb, Croatia
[2] Univ Hosp Dubrava, Cardiol Dept, Zagreb, Croatia
[3] Univ Hosp Dubrava, Intens Care Dept, Zagreb, Croatia
[4] Univ Zagreb, Fac Pharm & Biochem, Ctr Appl Pharm, Zagreb, Croatia
[5] Univ Hosp Dubrava, Hematol Dept, Av Gojka Suska 6, Zagreb, Croatia
[6] Univ Zagreb, Sch Med, Internal Med Dept, Zagreb, Croatia
[7] Univ Zagreb, Sch Med, Zagreb 10000, Croatia
关键词
Remdesivir; corticosteroids; prognosis; dexamethasone; methylprednisolone; prednisone;
D O I
10.1080/14656566.2024.2320255
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
IntroductionWe aimed to investigate patterns of corticosteroid use and their relationship with remdesivir use and clinical outcomes in a large real-life cohort of COVID-19 patients treated in a tertiary-level institution.MethodsWe retrospectively analyzed a total of 1558 severe and critical COVID-19 patients, including 779 patients treated with remdesivir and 779 matched control patients.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ResultsA total of 167 (10.7%) patients received none, 710 (45.6%) low, 539 (34.6%) high, and 142 (9.1%) very high corticosteroid doses. Patients treated with remdesivir had significantly longer exposure to corticosteroids, received higher average and maximal daily doses, and cumulative corticosteroid doses. In the multivariate analysis remdesivir use, lower cumulative comorbidity burden, higher severity of COVID-19 symptoms, and mechanical ventilation were recognized as mutually independent predictors of the use of higher corticosteroid doses. Higher corticosteroid doses were associated with significantly increased mortality.Among non-remdesivir treated patients, there was a U-shaped relationship between maximal daily corticosteroid dose and mortality. Among remdesivir treated patients gradual increase in mortality with increasing corticosteroid doses was observed.ConclusionPatterns of corticosteroid use differ regarding the use of remdesivir and may moderate its association with survival among severe and critical COVID-19 patients.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [31] Effect of Early and Delayed Treatment With Remdesivir on Mortality in Patients Hospitalized With COVID-19
    Makkar, Steve R.
    Hansen, Kristen
    Hotaling, Nathan
    Toler, Andrew
    Sidky, Hythem
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (02):
  • [32] Clinical Effectiveness and Safety of Remdesivir in Hemodialysis Patients with COVID-19
    Lim, Jeong-Hoo
    Park, Sang Don
    Jeon, Yena
    Chung, Yu Kyung
    Kwon, Jae Wan
    Jeon, You Hyun
    Jung, Hee-Yeon
    Park, Sun-Hee
    Kim, Chan-Duck
    Kim, Yong-Lim
    Kwon, Ki Tae
    Choi, Ji-Young
    Cho, Jang-Hee
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (11): : 2522 - 2525
  • [33] Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients
    Hegazy, Sahar K.
    Tharwat, Samar
    Hassan, Ahmed H.
    JOURNAL OF CLINICAL VIROLOGY PLUS, 2023, 3 (02):
  • [34] Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era
    Mozaffari, Essy
    Chandak, Aastha
    Gottlieb, Robert L.
    Chima-Melton, Chidinma
    Berry, Mark
    Amin, Alpesh N.
    Sax, Paul E.
    Kalil, Andre C.
    CLINICAL INFECTIOUS DISEASES, 2024, 79 : S149 - S159
  • [35] Managing hospitalized patients with COVID-19
    Stricker, Mike
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2023, 36 (10): : 16 - 21
  • [36] RETRACTED: Evaluating the Clinical Outcomes of Remdesivir Among Patients Admitted With COVID-19 in a Tertiary Care Hospital (Retracted Article)
    Butt, Ahmad G.
    Ahmed, Jahanzeb
    Shah, Syed Muhammad Huzaifa
    Capriles, Camilo Andres Avendano
    Al-Rihani, Hady
    Ahmed, Bilal
    Salman, Muhammad
    Devi, Arti
    Wali, Sher
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (11)
  • [37] Clinical outcomes and safety of remdesivir in hospitalized individuals with COVID-19, with or without severe renal impairment
    Chang, Min-Chi
    Wu, Ping-Feng
    Ho, Yu-Chien
    Lin, Wen-Ying
    Wu, Chia-Ying
    Liu, Szu-Yu
    Liu, Chia-Jen
    Lin, Yi-Tsung
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2024, 17 (07)
  • [38] Efffiicacy of Remdesivir on Clinical Outcomes in COVID-19 Patients: A Study in a Tertiary Care Hospital in Pakistan
    Shabbir, Bilquis
    Malik, Uzma
    Sarfraz, Zouina
    Saeed, Furqan
    Nawaz, Kashif
    Khalid, Iqra
    Gondal, Khalid Masud
    JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES, 2024, 14 (03):
  • [39] Safety outcomes of Remdesivir for treatment of COVID-19 hospitalised patients in Indonesia
    Hasmono, Didik
    Samirah, Samirah
    Hartono, Ruddy
    Subkhan, Mohammad
    Yoshida, Maria Angelia
    Leliga, Fenny Kesuma
    PHARMACY EDUCATION, 2024, 24 (03): : 348 - 352
  • [40] Bradycardia and Outcomes in COVID-19 Patients on Remdesivir: A Multicenter Retrospective Study
    Umeh, Chukwuemeka A.
    Maguwudze, Stella
    Kaur, Harpreet
    Dimowo, Ozivefueshe
    Naderi, Niyousha
    Safdarpour, Armin
    Hussein, Tarik
    Gupta, Rahul
    CARDIOLOGY RESEARCH, 2023, 14 (03) : 192 - 200